Clinical trial
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)
Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia Gravis (RAISE-XT)
ClinicalTrials.gov ID: NCT04225871
Sponsor: Ra Pharmaceuticals, Inc.
Information provided by: Ra Pharmaceuticals, Inc. (Responsible Party)
Last Update Posted: 2023-08-04
Brief Summary:
The RAISE-XT study is an open-label extension study to evaluate the long-term efficacy, safety, and tolerability of zilucoplan in subjects with gMG who have previously participated in a qualifying Ra Pharmaceuticals sponsored zilucoplan study.
OFFICIAL TITLE
A Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia Gravis
INTERVENTION / TREATMENT
Drug: zilucoplan (RA101495)
| Category | Value |
|---|---|
| Study Start (Actual) | 2019-12-23 |
| Primary Completion (Estimated) | 2026-06-02 |
| Study Completion (Estimated) | 2026-06-02 |
| Enrollment (Actual) | 200 |
| Study Type | Interventional |
| Phase | Phase 3 |
| Other Study ID Numbers | RA101495-02.302 |